ORI Capital
Venture capitalHong Kong · Pre-Seed–Late Stage · 15 people tracked
Investment thesis
ORI Capital backs innovative early-stage biotech companies on a global basis. Its funds focus on diagnostics, drug delivery, and therapeutics, targeting the disease areas responsible for the highest mortality rates, including cancer, cardiovascular disease, and neurodegenerative disease. The firm combines scientific insight with a mission to develop treatments that save lives, drawing on a mix of artificial and human intelligence in its investment approach.
Source: firm website, verified Aug 3, 2026.
Team · 15 people
from the firm's website & public directories
What they invest in
from 2 of 4 portfolio companiesBiotech ×2Healthtech ×2Medical Devices ×2Deep Tech ×1
HQs:United Kingdom×1
Investments · 4 tracked
founders shown can be your intro pathCG Oncology develops an investigational oncolytic immunotherapy for urologic cancer patients, specifically targeting BCG-unresponsive non-muscle invasive bladder cancer.
BiotechHealthtechMedical Devices
Co-investorsDecheng CapitalForesite CapitalLongitude CapitalPalm Drive CapitalRA CapitalTCG Crossover+2 more
Only company applying stem cell therapy to cure type 1 diabetes.
Orchard Therapeutics develops ex vivo autologous hematopoietic stem cell (HSC) gene therapies for genetic and other severe diseases, including rare inherited conditions such as ADA-SCID and metachromatic leukodystrophy.
BiotechDeep TechHealthtechMedical DevicesLondon, GB
Donald Kohn(Scientific Founder)Adrian Thrasher(Scientific Founder)Frank E. Thomas(Executive Officer)inSteven M. Altschuler(Director)John Curnutte(Director)
BoardBobby Gaspar(Scientific Founder)in
Co-investorsAlbionVCF-Prime CapitalForesite CapitalUCL Technology FundAgent CapitalBaillie Gifford+1 more
Boston-based biotech developing iPS-derived pancreatic islet therapies to cure insulin-dependent diabetes.
Exits · 1
IPOs and acquisitions across the tracked portfolioCG OncologyNASDAQ: CGON
Portfolio news
latest coverage across their companiesCG Oncology · investing.com · Aug 19, 2026
Orchard Therapeutics · x.com · Aug 8, 2026
Frequently asked questions
- What stage does ORI Capital invest at?
- ORI Capital invests at the Pre-Seed, Seed, Series A, Series B, Late Stage stages.
- What sectors does ORI Capital focus on?
- ORI Capital focuses on AI & Machine Learning, Biotech, Healthtech, Impact & Social Good, Medical Devices.
- Where is ORI Capital located?
- ORI Capital is headquartered in Hong Kong, HK.
Similar investors
Artesian is a venture capital manager offering Venture Capital as a Service (VCaaS): building and operating dedicated sole-LP venture funds and related infrastructure for institutions such as governments, corporations, industry bodies, universities, superannuation funds and family offices.
LIFTT is a venture capital holding company focused on deep tech technologies, using an operational, multi-vertical approach aimed at generating impact. It works to transform scientific research into high-impact companies, accelerating the path from lab to market.
MaRS is a Toronto-based innovation hub and accelerator that supports Canadian startups from pre-seed funding through international expansion, offering workspace, mentorship, investor and customer connections, and sector-focused programming.
Muirwoods Ventures is a venture capital firm investing in healthcare, technology, mobility, and the environment, with an emphasis on sustainability and mass-market solutions.